Singapore biotech startup Nanyang Biologics bets on AI drug discovery platform to unlock revenue
After investing six years in R&D, the firm is heading to Nasdaq via a US$1.5 billion Spac deal as it lands its first client
Add BT as a preferred source
[SINGAPORE] Drug development typically takes six to 10 years just to identify a viable molecule, but Singapore biotech firm Nanyang Biologics reckons it can do the job in six minutes.
Originally founded as a biopharma startup to develop cancer and cardiovascular therapies, the company simultaneously spent six years building an artificial intelligence (AI) platform to accelerate its own drug discovery work.
Now it has commercialised that technology as NYB.AI, positioning it as a tool for pharmaceutical and health supplement manufacturers looking to slash costs and timelines.
TRENDING NOW
Buyer for England striker Harry Kane’s former mansion must pay £3.4 million after abandoning deal
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
OUE Reit selling Crowne Plaza Changi Airport for S$500 million; unitholders to get special payout
Asean must retain more value as its digital economy races towards US$2 trillion: Indonesian minister
